Event Description
Topic
Emergency Department-Initiated Buprenorphine for Opioid Use Disorder
Presented By
Gail D'Onofrio, MD, Albert E. Kent Professor of Emergency Medicine and Professor
of Epidemiology (Chronic Diseases); Chair, Department of Emergency Medicine, Yale University School of Medicine; Physician‐in Chief of Emergency Services at Yale New
Haven Hospital
Learning Objectives
- Evaluate outcomes for Opioid Use Disorder in patients receiving buprenorphine through the Emergency Department and discuss supporting evidence
- Identify barriers and solutions to initiating buprenorphine in the Emergency Department
- Apply harm reduction strategies and components of the buprenorphine integration pathway
- Discuss innovative solutions for buprenorphine induction in the ED including different formulations of buprenorphine and high dose strategies
Accredidation Statement
Tower Health is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicans.
Accredidation Statement
Drexel University College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure
The course director and members of the planning committee do not have any relevant financial relationships with any commercial interests to disclose regarding today's presentation.
Faculty and all others who have ability to control the content of continuing medical education activities sponsored by Tower Health are expected to disclose to the audience whether they do or do not have any real or apparent conflict(s) of interest or other relationships related to the content of their presentation(s). The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Gail D'Onofrio, MD has no relevant financial relationship﴾s﴿ with ineligible companies whose primary business is producing, marketing, selling, reselling,
or distributing healthcare products used by or on patients to disclose.
Gail D'Onofrio, MD has indicated the presentation may include discussion of any off‐label uses of a product. Explanation Given: Will be discussing
and NIDA grant that has the use of CAM2038 a 7‐day extended release form of buprenorphine. This is under IND. We receive the medication from
NIDA and have no contact with the manufacturer |
